Title |
Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance
|
---|---|
Published in |
Molecular Cancer, August 2018
|
DOI | 10.1186/s12943-018-0865-2 |
Pubmed ID | |
Authors |
Jie Cao, Jianchang Wei, Ping Yang, Tong Zhang, Zhuanpeng Chen, Feng He, Fang Wei, Huacui Chen, He Hu, Junbin Zhong, Zhi Yang, Wensong Cai, Wanglin Li, Qiang Wang |
Abstract |
Genome-scale CRISPR-Cas9 Knockout Screening was applied to investigate novel targets in imatinib-resistant gastrointestinal stromal tumor (GIST). 20 genes and 2 miRNAs have been selected by total reads of sgRNA and sgRNA diversity, which has been further validated in imatinib-resistant GIST cells by CCK8 and qPCR analysis. Our study has finally revealed 9 genes (DBP, NR3C1, TCF12, TP53, ZNF12, SOCS6, ZFP36, ACYP1, and DRD1) involved in imatinib-resistant GIST-T1 cells. TP53 and SOCS6 may be the most promising candidate genes for imatinib-resistance due to the possible signaling pathway, such as apoptosis pathway and Wnt signaling pathway, JAK-STAT signaling pathway. It is necessary to perform more studies to discover novel targets in imatinib-resistant GIST, including DBP, NR3C1, TCF12, ZNF12, ZFP36, ACYP1 and DRD1. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 26 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 6 | 23% |
Student > Master | 4 | 15% |
Researcher | 3 | 12% |
Other | 2 | 8% |
Student > Ph. D. Student | 1 | 4% |
Other | 3 | 12% |
Unknown | 7 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 7 | 27% |
Medicine and Dentistry | 4 | 15% |
Agricultural and Biological Sciences | 3 | 12% |
Engineering | 2 | 8% |
Psychology | 1 | 4% |
Other | 1 | 4% |
Unknown | 8 | 31% |